Tandem Diabetes Care/$TNDM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ticker
$TNDM
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
2,650
ISIN
US8753722037
Website
TNDM Metrics
BasicAdvanced
$1B
-
-$2.80
1.53
-
Price and volume
Market cap
$1B
Beta
1.53
52-week high
$48.24
52-week low
$15.17
Average daily volume
1.6M
Financial strength
Current ratio
2.302
Quick ratio
1.718
Long term debt to equity
281.182
Total debt to equity
317.597
Interest coverage (TTM)
-12.46%
Profitability
EBITDA (TTM)
-75.068
Gross margin (TTM)
52.22%
Net profit margin (TTM)
-18.71%
Operating margin (TTM)
-9.35%
Effective tax rate (TTM)
-5.41%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-6.17%
Return on equity (TTM)
-92.31%
Valuation
Price to revenue (TTM)
1.053
Price to book
6.75
Price to tangible book (TTM)
6.75
Price to free cash flow (TTM)
-272.685
Free cash flow yield (TTM)
-0.37%
Free cash flow per share (TTM)
-5.78%
Growth
Revenue change (TTM)
27.65%
Earnings per share change (TTM)
28.88%
3-year revenue growth (CAGR)
10.04%
10-year revenue growth (CAGR)
33.67%
3-year earnings per share growth (CAGR)
215.35%
10-year earnings per share growth (CAGR)
-21.85%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Bulls say / Bears say
Tandem Diabetes Care's strategic partnership with Abbott to integrate their insulin delivery systems with Abbott's upcoming dual glucose-ketone sensor could enhance product offerings and market competitiveness. (stocktitan.net)
The company's first-quarter 2025 financial results showed a 22% increase in worldwide sales to $234.4 million, indicating strong market demand and operational performance. (stocktitan.net)
Tandem's t:slim X2 insulin pump received authorization for sale by Health Canada, expanding its market reach and potential revenue streams. (stocktitan.net)
Analysts have downgraded Tandem Diabetes Care's stock, with Morgan Stanley reducing its price target from $45.00 to $22.00, reflecting concerns about future performance. (etfdailynews.com)
The company reported a GAAP net loss of $130.6 million in Q1 2025, which may raise concerns about profitability and financial stability. (stocktitan.net)
Tandem Diabetes Care's stock price has declined significantly over the past year, with a 52-week low of $15.17, indicating potential investor concerns. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
TNDM News
AllArticlesVideos
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025
Business Wire·2 weeks ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Investors Business Daily·2 weeks ago
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tandem Diabetes Care stock?
Tandem Diabetes Care (TNDM) has a market cap of $1B as of July 15, 2025.
What is the P/E ratio for Tandem Diabetes Care stock?
The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of July 15, 2025.
Does Tandem Diabetes Care stock pay dividends?
No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Tandem Diabetes Care dividend payment date?
Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.